Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,201–1,210 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1201
- Medicine slug
- phenylephrine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 134
- Source count
- 30
- Agreement rate
- 1
- Recorded readings
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abd39d9c-fcda-4d01-8a58-1d54ba7ac651 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:170e63f1-23f4-4839-ab89-b81832d94a56 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d92631a6-bae8-493b-b4df-c563346607a8 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3ff0d1d-6f3f-4e3c-9407-6f3bf3a61e7d (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5788f8c6-f868-4b83-81dc-dc485d8716c0 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d89d7004-e20a-0a35-e053-2a95a90a7b78 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:386663e8-f1f6-cf14-e063-6394a90a68df (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bab505d-d5c8-8c3b-e063-6394a90ad18a (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cea0781-2513-4030-8568-62dec253f866 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fad93be4-32dd-44c1-a20f-2b0bb3b41929 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:744da574-dfc9-4a22-8983-2ee15be2ea84 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6feb2da2-05ef-47bb-9d8d-01b81ad69059 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6486d284-5189-4000-aa7d-67150e84a7b2 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d59ee85-08e5-452d-a09a-35fcc2a82b75 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:303bc1e6-0735-4ea1-84cd-6c1b621de0ed (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74192a42-0ff7-443b-9d8a-3096ef5c8e43 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:943638b7-527b-4724-a6b7-2018862396d4 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine hydrochloride plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d6973c4-4a69-4d49-9da7-d2a00df83ecb (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0930ec92-5654-078f-e063-6294a90aad02 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f715e4e-b269-b935-d2c9-003cb29770be (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7026b15-1228-4acb-beed-4474fcdbb972 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed Phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41eec9e9-6e94-15d4-e063-6394a90a98a2 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86abb371-3ac9-9f74-e053-2991aa0a66af (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18b65b44-fdd1-4385-b6f8-cf3cbdc8d0e6 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c02d53-fd3f-4fd7-abbe-f1358ea0891f (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1d3881f-fa9e-4d68-8ef0-9e03435fc292 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a05a70b9-f506-456f-a7aa-d9f9c80a7f12 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db313f72-a6bb-444f-949f-19b4aa6f61c0 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90a3853e-49d6-4536-be72-82cc875bcf74 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9f1d54-ea46-49c8-a33e-c94a61bc0460 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.
Projected row 1202
- Medicine slug
- phenylephrine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 134
- Source count
- 46
- Agreement rate
- 1
- Recorded readings
340L
- Numeric value
- 340
- Unit
- L
- Source records
- 46
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 46 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abd39d9c-fcda-4d01-8a58-1d54ba7ac651 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3f358dd-4a36-4808-9943-e01f88604be5 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d88a01c4-9681-2695-e053-2995a90a62ea (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a23ed28-3912-4398-b660-bf9ec3ee3926 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:170e63f1-23f4-4839-ab89-b81832d94a56 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb069778-d16e-40f9-9c02-5496adfcb5d2 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c600fe14-40b6-2b5a-e053-2a95a90aff98 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d92631a6-bae8-493b-b4df-c563346607a8 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a7ab4b-0afe-4463-a039-5be0323cf2f7 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3ff0d1d-6f3f-4e3c-9407-6f3bf3a61e7d (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5788f8c6-f868-4b83-81dc-dc485d8716c0 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d89d7004-e20a-0a35-e053-2a95a90a7b78 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e77b9c8-fa17-4aa4-adc8-ff716ab2e5d7 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:386663e8-f1f6-cf14-e063-6394a90a68df (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bab505d-d5c8-8c3b-e063-6394a90ad18a (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cea0781-2513-4030-8568-62dec253f866 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fad93be4-32dd-44c1-a20f-2b0bb3b41929 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71b8fb8a-e13a-246f-f7b4-aa912b9ccd54 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bb7af81-62ec-4ae7-8055-89453f7a161d (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1639934-8aa6-2364-e053-2995a90a9923 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:744da574-dfc9-4a22-8983-2ee15be2ea84 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6feb2da2-05ef-47bb-9d8d-01b81ad69059 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6486d284-5189-4000-aa7d-67150e84a7b2 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d59ee85-08e5-452d-a09a-35fcc2a82b75 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:303bc1e6-0735-4ea1-84cd-6c1b621de0ed (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74192a42-0ff7-443b-9d8a-3096ef5c8e43 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:943638b7-527b-4724-a6b7-2018862396d4 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d6973c4-4a69-4d49-9da7-d2a00df83ecb (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2096e12-cbeb-4084-9132-17c7ef46b7b9 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0930ec92-5654-078f-e063-6294a90aad02 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f454c289-5a31-4bd3-86a2-1281bf1ab14b (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4099cef4-44b1-ae3d-e063-6394a90aefac (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f715e4e-b269-b935-d2c9-003cb29770be (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2ba1b3e-94bc-494d-b0fe-4ab9dd61dddc (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7026b15-1228-4acb-beed-4474fcdbb972 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41eec9e9-6e94-15d4-e063-6394a90a98a2 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86abb371-3ac9-9f74-e053-2991aa0a66af (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18b65b44-fdd1-4385-b6f8-cf3cbdc8d0e6 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c02d53-fd3f-4fd7-abbe-f1358ea0891f (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b54a0c59-e5e4-4fd7-ba91-c991ce87b148 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1d3881f-fa9e-4d68-8ef0-9e03435fc292 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a05a70b9-f506-456f-a7aa-d9f9c80a7f12 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2dce7f1-6538-4747-9792-665eee45c0a9 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db313f72-a6bb-444f-949f-19b4aa6f61c0 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90a3853e-49d6-4536-be72-82cc875bcf74 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340L suggests a high distribution into organs and peripheral tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b9f1d54-ea46-49c8-a33e-c94a61bc0460 (opens source in a new tab)
Phenylephrine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution of approximately 340L suggests a high distribution into organs and peripheral tissues.
Projected row 1203
- Medicine slug
- phenytoin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 47
- Source count
- 47
- Agreement rate
- 0.617021
- Recorded readings
22 hours
- Numeric value
- 22
- Unit
- hours
- Source records
- 29
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 29 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afdf66e0-5f99-444e-bc06-2fdddc507f5c (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f94c791-8b07-4b41-927e-c9f28bec5f60 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7bfb3aa-5226-4a48-8156-a9ecc4536fdf (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5362ea50-38a4-48b4-a85b-d634c3d8b91a (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:844a16db-17d5-44da-819d-54f3e19cfec2 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df0bf42b-ce9a-42c3-8c24-46f1ea3bd214 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Pharmacokinetics and Drug Metabolism The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46d5c0d1-a97b-46d9-8cf4-994780673337 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29b8d0a2-a96e-46a5-e063-6394a90a7113 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b64cb11-673a-41ec-9b2a-1e194ae5eb0c (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c2542b8-ac54-e85d-e063-6294a90a759b (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b4c2885-eae0-4c88-ada3-62a699df1dbb (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09daf485-3355-44cb-92af-072dd281e129 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:093fd736-5971-47af-b4ef-08c1696cebe8 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bc82d23-3950-f181-e063-6394a90ad565 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4353734-29b0-4027-824d-2fc97f778c67 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e33ce05d-9c60-4ede-8b13-e8c41a3de25d (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2c74e35-ed8d-4ea6-b7a5-7be0b0155c15 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36262a4c-33f1-40a5-e063-6394a90ad36a (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:601f7353-225d-4a5d-9810-3869c2c21874 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b660c3-7d88-77b2-e063-6294a90a0286 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:363cd347-d25e-42b9-9ce7-30642f3cb353 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef4e97a7-cd18-47a9-a016-2eca5481a87e (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c40f66cc-6f4a-4b29-84ba-d265e4848735 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9a1059e-63a2-486e-aa50-eda388f79525 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e467c02-49a0-4b62-b537-430fdfa4f10e (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37943ec1-a8d2-42df-967e-6f96f84c017b (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9fe4c92-2761-4cb4-9cf3-7066e240e014 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4459837-da26-4c97-8587-32eb1f682d58 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f339f9e4-b289-4efe-82b9-46c57d1dc277 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
10 to 15 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7607ddff-2f1c-272c-e053-2991aa0a1ab3 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a52cf1bd-dc1f-47be-aba8-29066d9a50fb (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:035a8d4e-2063-4240-83cb-d7eebcabe301 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6922f32f-8bed-4c09-8103-27987bcbd104 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0aac9dcd-c4df-84d9-e063-6294a90a0376 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:763b549d-9b78-09dd-e053-2a91aa0aec7f (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:889dd22c-46f0-48d0-b18e-a3783c5fa653 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ad1be7b-a1a4-4a2a-bf9b-d22b350aa6e7 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43060ca9-58a7-3371-e063-6294a90a5799 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination The serum half-life in man after intravenous administration ranges from 10 to 15 hours.
14 hours
- Numeric value
- 14
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3580e6a8-f7c3-44a0-a1eb-2a84ae589d21 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using Phenytoin Infatabs have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98bd1d9f-b1a4-49eb-a0b4-a790265710dd (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using phenytoin chewable tablets have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e95cad66-b5f9-4802-a35f-fed340bf09ab (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using phenytoin chewable tablets have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08a9d26b-4419-43ec-98f3-43d4534c2e76 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using phenytoin chewable tablets have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca119a89-2394-4d34-8078-cd1fa4e8e2f1 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using Dilantin Infatabs have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78b38e7b-1460-4adc-b738-320ffa6259c2 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using phenytoin chewable tablets have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:352007dd-0587-4597-8338-c13eda4c5d63 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using phenytoin chewable tablets have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31e8a777-75b1-4f48-9682-0bcc3189ad26 (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using phenytoin chewable tablets have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d240b2b-bc5c-4989-a20b-54ed37a09a4f (opens source in a new tab)
Phenytoin label
Version not recorded · Effective date not recorded
Elimination Clinical studies using Phenytoin Infatabs have shown an average plasma half-life of 14 hours with a range of 7 to 29 hours.
Projected row 1204
- Medicine slug
- pilocarpine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
0.76 hours
- Numeric value
- 0.76
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:438cfaa3-b5f6-4d75-ac22-b0b4e07bb118 (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06c054af-62b4-4373-813a-9bb2e5c92316 (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b85547d8-fcec-323d-e053-2995a90a4e7e (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f950741-fd3f-4bf7-83b0-f5aa9dbceb76 (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a73a702-c5e2-44ea-81c8-ee7e60852c41 (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62eda83d-d043-4c7e-8fcf-75d05efbf35b (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6272ccac-b543-404d-9938-8583bb59ed2c (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 mg or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb97323d-acec-4e4a-af16-efef66d969dc (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8db0db4f-55ad-46b2-af50-e71b4a763aaa (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:610022b7-7dc9-405a-a580-104657f43bdf (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: In a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a86a7b63-5f6a-4c10-9270-24c7b7d50437 (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
Pharmacokinetics: n a multiple-dose pharmacokinetic study in male volunteers following 2 days of 5 or 10 mg of oral pilocarpine hydrochloride tablets given at 8 a.m., noontime, and 6 p.m., the mean elimination half-life was 0.76 hours for the 5 mg dose and 1.35 hours for the 10 mg dose.
Projected row 1205
- Medicine slug
- pilocarpine
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 16
- Source count
- 3
- Agreement rate
- 0.666667
- Recorded readings
0.3 hours
- Numeric value
- 0.3
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93e37b61-7b90-4740-b0b4-17d39d3b03f6 (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
The median T max value on Day 30 was 0.3 hours post-dose with a range from 0.2 hours to 0.5 hours post-dose. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Pilocarpine hydrochloride is a cholinergic muscarinic agonist which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d806897-8a2a-4518-8c68-0ec3b778de50 (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
The median T max value on Day 30 was 0.3 hours postdose with a range from 0.2 to 0.5 hours postdose.
2.20 hr
- Numeric value
- 2.2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ee2a840-1203-473a-aa42-316a3ddf2fbe (opens source in a new tab)
Pilocarpine label
Version not recorded · Effective date not recorded
The overall median T max in plasma after Day 8 dosing was 2.20 hr and the mean (SD) overall plasma C max and AUC 0-t after Day 8 dosing were 897.2 (287.2) pg/mL and 2699 (741.4) hr*pg/mL, respectively.
Projected row 1206
- Medicine slug
- pimavanserin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:403b6540-c53d-4e92-91b4-36ca6338b2b1 (opens source in a new tab)
Pimavanserin label
Version not recorded · Effective date not recorded
The formation of the major circulating N-desmethylated metabolite AC-279 (active) from pimavanserin occurs with a median T max of 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e6bea44-57d6-4bac-9328-46e1ee59f83b (opens source in a new tab)
Pimavanserin label
Version not recorded · Effective date not recorded
The formation of the major circulating N- desmethylated metabolite AC-279 (active) from pimavanserin occurs with a median T max of 6 hours.
Projected row 1207
- Medicine slug
- pimecrolimus
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
99.5%
- Numeric value
- 99.5
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc8708ec-16be-4c27-8a5e-bf84723408fe (opens source in a new tab)
Pimecrolimus label
Version not recorded · Effective date not recorded
Distribution Laboratory in vitro plasma protein binding studies using equilibrium gel filtration have shown that 99.5% of pimecrolimus in plasma is bound to proteins over the pimecrolimus concentration range of 2-100 ng/mL tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5b0403a-065f-42e3-96d6-7dcb9ab127d3 (opens source in a new tab)
Pimecrolimus label
Version not recorded · Effective date not recorded
Distribution Laboratory in vitro plasma protein binding studies using equilibrium gel filtration have shown that 99.5% of pimecrolimus in plasma is bound to proteins over the pimecrolimus concentration range of 2 ng/mL to 100 ng/mL tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac52a235-1b6f-47a2-b3d9-8d538eeae02f (opens source in a new tab)
Pimecrolimus label
Version not recorded · Effective date not recorded
Distribution Laboratory in vitro plasma protein binding studies using equilibrium gel filtration have shown that 99.5% of pimecrolimus in plasma is bound to proteins over the pimecrolimus concentration range of 2 to 100 ng/mL tested.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6601e43e-ce7d-446a-8568-8e7b24b86f06 (opens source in a new tab)
Pimecrolimus label
Version not recorded · Effective date not recorded
Distribution Laboratory in vitro plasma protein binding studies using equilibrium gel filtration have shown that 99.5% of pimecrolimus in plasma is bound to proteins over the pimecrolimus concentration range of 2-100 ng/mL tested.
Projected row 1208
- Medicine slug
- pimozide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
55 hours
- Numeric value
- 55
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70b079e2-a1f7-4a93-8685-d60a4d7c1280 (opens source in a new tab)
Pimozide label
Version not recorded · Effective date not recorded
The mean serum elimination half-life of pimozide in schizophrenic patients was approximately 55 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e954fc2-fdff-486c-beb6-2b8ace717081 (opens source in a new tab)
Pimozide label
Version not recorded · Effective date not recorded
The mean serum elimination half-life of pimozide in schizophrenic patients was approximately 55 hours.
Projected row 1209
- Medicine slug
- pindolol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
8 hours
- Numeric value
- 8
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0daed7b3-6017-4611-8c3a-2f390470f8bc (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b331a73f-bf7b-4442-8901-36d016530279 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79a8d97b-9461-4914-bcbb-f6f64a39e5e7 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:611be921-e9b6-4800-80b2-c2d4f677cdb2 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f91e5715-e37d-45fa-97a7-4d32fbd51060 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efdb0189-37b5-45d6-b92c-1157bb9df789 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f529ff35-f82b-4a3a-96b4-096bfc8e81b5 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1049edf-376e-317b-e053-2995a90a2aac (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fb36f8f-11fe-498e-8667-daeccf8b2273 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22b95e96-ead9-4149-badb-7d33077e82ec (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8498aead-0aef-4cd8-a191-05cae57a55e5 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma.
Projected row 1210
- Medicine slug
- pindolol
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0daed7b3-6017-4611-8c3a-2f390470f8bc (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b331a73f-bf7b-4442-8901-36d016530279 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79a8d97b-9461-4914-bcbb-f6f64a39e5e7 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:611be921-e9b6-4800-80b2-c2d4f677cdb2 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f91e5715-e37d-45fa-97a7-4d32fbd51060 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol tablets are rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efdb0189-37b5-45d6-b92c-1157bb9df789 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f529ff35-f82b-4a3a-96b4-096bfc8e81b5 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol tablets are rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1049edf-376e-317b-e053-2995a90a2aac (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fb36f8f-11fe-498e-8667-daeccf8b2273 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol tablets are rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22b95e96-ead9-4149-badb-7d33077e82ec (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8498aead-0aef-4cd8-a191-05cae57a55e5 (opens source in a new tab)
Pindolol label
Version not recorded · Effective date not recorded
PHARMACOKINETICS AND METABOLISM Pindolol is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1200Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.